INSERM U1052 - Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; University of Lyon, UMR_S1052, CRCL, 69008 Lyon, France; Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, France.
Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, France.
Curr Opin Virol. 2018 Jun;30:80-89. doi: 10.1016/j.coviro.2018.04.006. Epub 2018 May 16.
The latest generation of nucleo(t)side analogs (NAs) provide robust virus suppression with high barrier to resistance. Long term NAs treatment is associated with a partial restoration in HBV-specific T-cell functions, regression of fibrosis, no disease progression and a reduction of HCC risk but rarely lead to cure and life-long treatments is often required. New insights into the hepatitis B viral life cycle and the host immune response have expanded the potential targets for drug therapies with interesting antiviral candidates and novel immunotherapeutic approaches in early stage development. Here we review the mode of action of current drugs (NAs and PEG IFN) and new classes of anti-HBV compounds, focusing on the possible role of nucleo(t)side analogs in future combination therapies.
最新一代的核（苷）酸类似物（NAs）提供了强大的病毒抑制作用，具有很高的耐药屏障。长期使用 NAs 治疗与 HBV 特异性 T 细胞功能的部分恢复、纤维化的消退、无疾病进展和 HCC 风险的降低有关，但很少能治愈，通常需要终身治疗。对乙型肝炎病毒生命周期和宿主免疫反应的新认识扩展了药物治疗的潜在靶点，具有有趣的抗病毒候选药物和新型免疫治疗方法处于早期开发阶段。在这里，我们回顾了当前药物（NAs 和 PEG IFN）和新型抗乙型肝炎化合物的作用模式，重点讨论了核（苷）酸类似物在未来联合治疗中的可能作用。
